|
1
|
Holland EC: Glioblastoma multiforme: The
terminator. Proc Natl Acad Sci USA. 97:pp. 6242–6244. 2000;
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Louis DN, Pomeroy SL and Cairncross JG:
Focus on central nervous system neoplasia. Cancer Cell. 1:125–128.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Nakada M, Nakada S, Demuth T, Tran NL,
Hoelzinger DB and Berens ME: Molecular targets of glioma invasion.
Cell Mol Life Sci. 64:458–78. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Omay SB and Vogelbaum MA: Current concepts
and newer developments in the treatment of malignant gliomas.
Indian J Cancer. 46:88–95. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Lima FR, Kahn SA, Soletti RC, Biasoli D,
Alves T, da Fonseca AC, Garcia C, Romão L, Brito J, Holanda-Afonso
R, et al: Glioblastoma: Therapeutic challenges, what lies ahead.
Biochim Biophys Acta. 1826:338–349. 2012.PubMed/NCBI
|
|
6
|
Altieri DC: Survivin, cancer networks and
pathway-directed drug discovery. Nat Rev Cancer. 8:61–70. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Ke HL, Tu HP, Lin HH, Chai CY, Chang LL,
Li WM, Li CC, Lee YC, Yeh HC, Wu WJ and Bau DT: Cyclooxygenase-2
(COX-2) up-regulation is a prognostic marker for poor clinical
outcome of upper tract urothelial cancer. Anticancer Res.
32:4111–4116. 2012.PubMed/NCBI
|
|
8
|
Cebola I and Peinado MA: Epigenetic
deregulation of the COX pathway in cancer. Prog Lipid Res.
51:301–313. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rödel F, Reichert S, Sprenger T, Gaipl US,
Mirsch J, Liersch T, Fulda S and Rödel C: The Role of Survivin for
Radiation Oncology: Moving Beyond Apoptosis Inhibition. Curr Med
Chem. 18:191–199. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kanwar JR, Kamalapuram SK and Kanwar RK:
Targeting survivin in cancer: Patent review. Expert Opin Ther Pat.
20:1723–1737. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen XQ, Yang S, Li ZY, Lu HS, Kang MQ and
Lin TY: Effects and mechanism of downregulation of survivin
expression by RNA interference on proliferationand apoptosis of
lung cancer cells. Mol Med Rep. 5:917–922. 2012.PubMed/NCBI
|
|
12
|
Louis DN, Ohgaki H, Wiestler OD, Cavenee
WK, Burger PC, Jouvet A, Scheithauer BW and Kleihues P: The 2007
WHO classification of tumours of the central nervous system. Acta
Neuropathol. 114:97–1099. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Remmele W and Stegner HE: Recommendation
for uniform definition of an immunoreactive score (IRS) for
immunohistochemical estrogen receptor detection (ER-ICA) in breast
cancer tissue. Pathologe. 8:138–140. 1987.(In German). PubMed/NCBI
|
|
14
|
Fesik SW: Promoting apoptosis as a
strategy for cancer drug discovery. Nat Rev Cancer. 5:876–885.
2005. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Trifan OC and Hla T: Cyclooxygenase-2
modulates cellular growth and promotes tumorigenesis. J Cell Mol
Med. 7:207–222. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Altieri DC: Survivin, versatile modulation
of cell division and apoptosis in cancer. Oncogene. 22:8581–8589.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Grösch S, Maier TJ, Schiffmann S and
Geisslinger G: Cyclooxygenase-2 (COX-2)-independent
anticarcinogenic effects of selective COX-2 inhibitors. J Natl
Cancer Inst. 98:736–47. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kim YM, Shin YK, Jun HJ, Rha SY and Pyo H:
Systematic analyses of genes associated with radiosensitizing
effect by celecoxib, a specific cyclooxygenase-2 inhibitor. Radiat
Res. 52:752–765. 2011. View Article : Google Scholar
|
|
19
|
Hoellen F, Kelling K, Dittmer C, Diedrich
K, Friedrich M and Thill M: Impact of cyclooxygenase-2 in breast
cancer. Anticancer Res. 31:4359–4367. 2011.PubMed/NCBI
|
|
20
|
Moreira L and Castells A: Cyclooxygenase
as a target for colorectal cancer chemoprevention. Curr Drug
Targets. 12:1888–1894. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zimmermann KC, Sarbia M, Weber AA,
Borchard F, Gabbert HE and Schrör K: Cyclooxygenase-2 expression in
human esophageal carcinoma. Cancer Res. 59:198–204. 1999.PubMed/NCBI
|
|
22
|
Greenhough A, Smartt HJ, Moore AE, Roberts
HR, Williams AC, Paraskeva C and Kaidi A: The COX-2/PGE 2 pathway:
Key roles in the hallmarks of cancer and adaptation to the tumour
microenvironment. Carcinogenesis. 30:377–386. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Temel SG and Kahveci Z: Cyclooxygenase-2
expression in astrocytes and microgliain human oligodendroglioma
and astrocytoma. J Mol Histol. 40:369–377. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
El-Sayed M and Taha MM:
Immunohistochemical expression of cycloxygenase-2 in astrocytoma:
Correlation with Angiogenesis, tumor progression and survival. Turk
Neurosurg. 21:27–35. 2011.PubMed/NCBI
|
|
25
|
Altieri DC: Targeting survivin in cancer.
Cancer Lett. 332:225–228. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Liu W, Zhu F, Jiang Y, Sun D, Yang B and
Yan H: SiRNA targeting survivin inhibits the growth and enhances
the chemosensitivity of hepatocellularcarcinoma cells. Oncol Rep.
29:1183–1188. 2013.PubMed/NCBI
|
|
27
|
Mobahat M, Narendran A and Riabowol K:
Survivin as a preferential target for cancer therapy. Int J Mol
Sci. 15:2494–2516. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jeyaprakash AA, Klein UR, Lindner D, Ebert
J, Nigg EA and Conti E: Structure of a Survivin-Borealin-INCENP
core complex reveals how chromosomal passengers travel together.
Cell. 131:271–285. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Altieri DC: Survivin-The inconvenient IAP.
Semin Cell Dev Biol. 39:91–96. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shirai K, Suzuki Y, Oka K, Noda SE, Katoh
H, Suzuki Y, Itoh J, Itoh H, Ishiuchi S, Sakurai H, et al: Nuclear
survivin expression predicts poorer prognosis in glioblastoma. J
Neurooncol. 91:353–358. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chakravarti A, Noll E, Black PM,
Finkelstein DF, Finkelstein DM, Dyson NJ and Loeffler JS:
Quantitatively determined survivin expression levels are of
prognostic value in human gliomas. Oncol. 20:1063–1068. 2002.
|
|
32
|
Kogiku M, Ohsawa I, Matsumoto K, Sugisaki
Y, Takahashi H, Teramoto A and Ohta S: Prognosis of glioma patients
by combined immunostaining for survivin, Ki-67 and epidermal growth
factor receptor. J Clin Neurosci. 15:1198–1203. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Mehar A, Macanas-Pirard P, Mizokami A,
Takahashi Y, Kass GE and Coley HM: The effects of cyclooxygenase-2
expression in prostate cancer cells: Modulation of response to
cytotoxic agents. J Pharmocol Exp Ther. 324:1181–1187. 2008.
View Article : Google Scholar
|
|
34
|
Athanassiadou P, Grapsa D, Athanassiades
P, Gonidi M, Athanassiadou AM, Tsipis A and Patsouris E: The
prognostic significance of COX-2 and survivin expression in ovarian
cancer. Pathol Res Pract. 204:241–249. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Erkanli S, Bolat F, Kayaselcuk F, Demirhan
B and Kuscu E: COX-2 and survivin are overexpressed and positively
correlated in endometrial carcinoma. Gynecol Oncol. 104:320–325.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ren Z, Zhang LZ and Wang RZ: Effect of
celecoxib on proliferation, apoptosis and Survivin expression in
human glioma cell line U251. Chin J Can. 29:294–299. 2010.
View Article : Google Scholar
|
|
37
|
Schetter AJ, Heegaard NH and Harris CC:
Inflammation and cancer: Interweaving micro RNA, free radical,
cytokine and p53 pathways. Carcinogenesis. 31:37–49. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Rödel F, Frey B, Leitmann W, Capalbo G,
Weiss C and Rödel C: Survivin antisense oligonucleotides
effectively radiosensitize colorectal cancer cells in both tissues
culture and murine xenograft models. Int J Radiat oncol Biol Phys.
71:247–255. 2008. View Article : Google Scholar : PubMed/NCBI
|
